Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;38(5):658-661.
doi: 10.1097/ICO.0000000000001865.

Sjögren's Syndrome: More Than Just Dry Eye

Esen K Akpek  1 , Vatinee Y Bunya  2 , Ian J Saldanha  3
Affiliations
Review

Sjögren's Syndrome: More Than Just Dry Eye

Esen K Akpek et al. Cornea. 2019 May.

Abstract

Purpose: Sjögren's syndrome (SS) is a common autoimmune disease affecting about four million Americans. Although approximately 1 in 10 patients with clinically-significant aqueous deficient dry eye has underlying SS, widespread underappreciation of SS leads to significant underdiagnosis, delays in diagnosis, and consequent morbidity and mortality. The purpose of this article is to illustrate that in addition to dry eye, SS can cause serious, vision-threatening extraglandular ocular manifestations.

Methods: We conducted a narrative review of studies that have examined the dry eye and extraglandular ocular complications of SS.

Results: SS-related dry eye is a progressive condition with major negative impact on the quality-of-life of afflicted patients, not only due to symptoms of ocular discomfort but also visual dysfunction. In addition, SS can lead to corneal melt/perforation, uveitis, scleritis, retinal vasculitis, and optic neuritis. A major problem with currently-available SS disease activity measurement instruments is the lack of domains evaluating dry eye-related visual dysfunction. For example, one of the most commonly-used instruments for assessing patient symptoms in SS (the EULAR Sjögren's Syndrome Patient Reported Index [ESSPRI]) only includes one item (out of three) that addresses the severity of overall dryness, without mention of dry eye symptoms or vision-related quality-of-life. Similarly, no extraglandular ocular complications are included in currently-available SS disease activity instruments (e.g., the EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI]).

Conclusions: There needs to be a paradigm shift in which eye care providers and rheumatologists become more familiar with various SS-related extraglandular ocular manifestations. Existing disease activity measurement instruments must incorporate dry eye symptoms, particularly those related to visual dysfunction. An evidence-based screening algorithm for determining which patients with dry eye should be tested for underlying SS may be particularly helpful in preventing delays in diagnosis.

PubMed Disclaimer

Conflict of interest statement

E. K. Akpek is an uncompensated member of the Board of Directors of the Sjögren’s Syndrome Foundation, Bethesda, MD. The other authors have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
Slit-lamp photograph of a patient with Sjögren syndrome who presented with sterile corneal melt and perforation.
FIGURE 2.
FIGURE 2.
Slit-lamp photograph of a patient with necrotizing scleritis due to primary Sjögren syndrome.
See this image and copyright information in PMC

References

    1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58:15–25. - PubMed
    1. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164:1275–1284. - PubMed
    1. Sjögren H On knowledge of kerataconjunctivitis sicca: keratitis filiformis due to lacrimal gland hypofunction. Acta Opthalmol. 1933;1: 1–151.
    1. Brito-Zeron P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjogren’s syndrome. Curr Opin Rheumatol. 2014;26:520–527. - PubMed
    1. Liang Y, Yang Z, Qin B, et al. Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73:1151–1156. - PubMed